Short answer
Elevance Health (ELV) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Peter Haytaian exits EVP/President of Carelon role effective May 4, 2026, citing family commitments: not a dispute-driven departure.
Elevance Health 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Peter Haytaian exits EVP/President of Carelon role effective May 4, 2026, citing family commitments: not a dispute-driven departure
- Transitions to Special Advisor through Dec 31, 2026, providing ~8-month runway for leadership transition at Carelon
- Carelon is Elevance's health services segment: leadership continuity here is material given its strategic growth priority
- No successor named in this filing; investor focus should shift to Exhibit 99.1 press release for replacement details
Item 7.01 · Regulation FD Disclosure
- Reg FD disclosure: forward-looking statement boilerplate only; no financial data, guidance, or material new information disclosed
- Key risk factors flagged: healthcare cost trends, Medicare/Medicaid compliance, CMS Star Ratings, cyber threats, and AI system failures
- Elevated sector-specific risks noted: negative industry sentiment (post-UnitedHealthcare event context) and pharmacy services agreement with CaremarkPCS Health
- Shareholder return risks highlighted: dividend restrictions, share repurchase capacity, and substantial outstanding debt load all cited as potential constraints
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Elevance Health 8-K filings
Get the next ELV 8-K as it lands
Follow ELV for push alerts, or ask the research agent what this filing means.